Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switching from spironolactone to finerenone in primary aldosteronism
TCTR20260812004Phase 2Recruiting
- Sponsor
- Division of Endocrinology and Metabolism, Department of Medicine, Faculty of Medicine, Chulalongkorn University.
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of spironolactone, finerenone in primary aldosteronism (PA), sponsored by Division of Endocrinology and Metabolism, Department of Medicine, Faculty of Medicine, Chulalongkorn University.. Started Jul 2026; status: recruiting.
02
Drugs
spironolactonefinerenone
03
Conditions
primary aldosteronism (PA)
Beyond the preview
Go deeper on TCTR20260812004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20260812004.